Abstract

Paclitaxel, an antimicrotubular agent used in the treatment of ovarian and breast cancer, was encapsulated in nanoparticles of poly(DL-lactide-co-glycolide) and poly(ε-caprolactone) polymers using the double emulsion-solvent evaporation technique. The morphology, size distribution, drug encapsulation efficiency, thermal degradation and in-vitro drug release profile were characterized. High-performance liquid chromatography was used to determine the drug encapsulation efficiency and in-vitro drug release profile. MCF-7 breast cancer cells were used to evaluate the cytotoxicity (MTT assay), the cellular uptake and the cell cycle. The particle size was in the range of 200-400 nm. Poly(lactide-co-glycolide) nanoparticles showed more effective cellular uptake compared with those of poly(ε-caprolactone). Unloaded nanoparticles were found to be cytocompatible on MCF-7 cells and paclitaxel formulations showed efficacy in killing MCF-7 cells. Paclitaxel-loaded nanoparticles induced the release of the drug-blocking cells in the G2/M phase. Paclitaxel-loaded nanoparticles may be considered a promising drug delivery system in the evaluation of an in-vivo model.

Links

Publisher Full Text

Authors

López-Gasco P, Iglesias I, Benedí J, Lozano R, Blanco MD

Institution

Department of Pharmacology, Complutense University of Madrid, Madrid, Spain.

Source

Anti-cancer drugs 23:9 2012 Oct pg 947-58

MeSH

Cell Culture Techniques
Cell Cycle
Cell Survival
Chromatography, High Pressure Liquid
Drug Carriers
Drug Compounding
Endocytosis
Flow Cytometry
Humans
MCF-7 Cells
Microscopy, Fluorescence
Nanoparticles
Paclitaxel
Particle Size
Polyesters
Polyglactin 910
Solubility
Surface Properties
Thermogravimetry

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22713593